目的观察通心络胶囊治疗心脏X综合征合并糖尿病患者的治疗效果。方法选择2014年3月—2017年1月湖北省鄂州市中心医院心内科收治的心脏X综合征合并糖尿病患者68例作为研究对象,将其按随机数字表法分为对照组(n=34)和观察组(n=34)。对照...目的观察通心络胶囊治疗心脏X综合征合并糖尿病患者的治疗效果。方法选择2014年3月—2017年1月湖北省鄂州市中心医院心内科收治的心脏X综合征合并糖尿病患者68例作为研究对象,将其按随机数字表法分为对照组(n=34)和观察组(n=34)。对照组患者口服单硝酸异山梨酯缓释片、拜阿司匹林片、琥珀酸美托洛尔缓释片或盐酸地尔硫片治疗。观察组患者在对照组基础上,加服通心络胶囊治疗。3个月后观察2组临床疗效,对2组患者的血清内皮素-1(ET-1)、NO、ET-1/NO水平、劳力型心绞痛发作频率、运动平板试验结果进行比较。结果观察组总有效率为82.35%,显著高于对照组的58.82%(χ~2=6.575,P=0.037)。与对照组比较,观察组血清NO明显升高,ET-1水平及ET-1/NO明显降低(t=3.274、2.873、4.233,P=0.002、0.003、0.000)。观察组平板运动试验时总运动时间、ST段压低1 m V的时间、ST段最大压低幅度的改善情况优于对照组(t=3.237、2.704、2.674,P=0.008、0.021、0.010)。结论通心络胶囊治疗心脏X综合征合并糖尿病患者疗效显著。展开更多
Objective： To evaluate the efficacy and safety of Tongxinluo Capsule（通心络胶囊, TXL） for patients with cardiac syndrome X（CSX）. Methods： Randomized controlled trials（RCTs） regarding TXL in the treatment of CS...Objective： To evaluate the efficacy and safety of Tongxinluo Capsule（通心络胶囊, TXL） for patients with cardiac syndrome X（CSX）. Methods： Randomized controlled trials（RCTs） regarding TXL in the treatment of CSX were searched in Chinese Biomedicine Literature Database, China National Knowledge Infrastructure, Chinese Scientific Journal Database, Wanfang Database, Pub Med, EMBASE, Cochrane Central Register of Controlled Trial, websites of the Chinese and International Clinical Trial Registry platform up to June 30, 2015. The intervention was either TXL alone or TXL combined with conventional treatment, while the control intervention was conventional treatment with or without placebo. Data extraction, methodological quality assessment and data analyses were performed according to the Cochrane criteria. The primary outcome was a composite event of death, acute myocardial infarction（AMI）, angina requiring hospitalization, revascularization, and heart failure. The secondary outcome measures were angina symptom improvement, electrocardiograph（ECG） improvement, and serum endothelin-1（ET-1） level. The adverse events were also recorded. RevMan 5.3 software was applied for data analyses. Results： Twelve RCTs（696 patients） were included. Compared with conventional treatment, the addition of TXL to conventional treatment showed some benefits on relieving angina symptoms [risk ratio（RR）： 1.46, 95% confidence interval（CI）（1.25, 1.71）, P〈0.01], and improving ECG [RR： 1.45, 95% CI（1.21, 1.74）, P〈0.01]. The pooled result did not support a benefit of TXL on reducing the incidence of primary outcome [RR： 0.20, 95% CI（0.02, 1.61）, P=0.13]. In addition, TXL decreased serum ET-1 concentration of CSX patients [standardized mean number： –1.63, 95% CI（–2.29, –0.96）, P〈0.01]. No serious adverse events were reported. Conclusions： TXL documents potential benefits on attenuating angina symptoms, improving ECG and decreasing serum ET-1 level for CSX patients. 展开更多
Objective： To evaluate the clinical effect of Liqi Kuanxiong Huoxue method （宽胸活血,LKH, traditional Chinese medicine, TCM therapeutic method for regulating qi, relieving chest stuffiness and promoting blood circul...Objective： To evaluate the clinical effect of Liqi Kuanxiong Huoxue method （宽胸活血,LKH, traditional Chinese medicine, TCM therapeutic method for regulating qi, relieving chest stuffiness and promoting blood circulation） in treating patients with cardiac syndrome X （CSX）. Methods： The prospective, non-randomized controlled study was conducted on 51 selected patients with CSX, who were non-randomly assigned to 2 groups, the treated group treated with LKH in addition to the conventional treatment （32 patients）, and the control group treated with conventional treatment （19 patients） like nitrate, diltiazem hydrochloride, etc. The treatment course was 14 days. The changes of such symptoms as angina pectoris, TCM syndrome and indexes of treadmill exercise test before and after treatment were observed. Results： After treatment, such symptoms as chest pain and stuffy feeling and palpitation in the treated group were improved more than those in the control group （P〈0.05）; the total effective rate on angina pectoris and TCM syndrome in the treated group was better than that in the control group （P〈0.05）. The treadmill exercise test showed that the maximal metabolic equivalent （Max MET）, the time of angina onset and ST segment depression by 0.1 mV were obviously improved after treatment in both groups, but the improvement in the treated group was better than that in the control group respectively （P〈0.05）. Conclusion： The LKH method could reduce the frequency of angina attacks and improve the clinical condition of patients with CSX.展开更多
文摘目的观察通心络胶囊治疗心脏X综合征合并糖尿病患者的治疗效果。方法选择2014年3月—2017年1月湖北省鄂州市中心医院心内科收治的心脏X综合征合并糖尿病患者68例作为研究对象,将其按随机数字表法分为对照组(n=34)和观察组(n=34)。对照组患者口服单硝酸异山梨酯缓释片、拜阿司匹林片、琥珀酸美托洛尔缓释片或盐酸地尔硫片治疗。观察组患者在对照组基础上,加服通心络胶囊治疗。3个月后观察2组临床疗效,对2组患者的血清内皮素-1(ET-1)、NO、ET-1/NO水平、劳力型心绞痛发作频率、运动平板试验结果进行比较。结果观察组总有效率为82.35%,显著高于对照组的58.82%(χ~2=6.575,P=0.037)。与对照组比较,观察组血清NO明显升高,ET-1水平及ET-1/NO明显降低(t=3.274、2.873、4.233,P=0.002、0.003、0.000)。观察组平板运动试验时总运动时间、ST段压低1 m V的时间、ST段最大压低幅度的改善情况优于对照组(t=3.237、2.704、2.674,P=0.008、0.021、0.010)。结论通心络胶囊治疗心脏X综合征合并糖尿病患者疗效显著。
基金Supported by the National Science and Technology Support Plan of China(No.2013BAI02B01)
文摘Objective： To evaluate the efficacy and safety of Tongxinluo Capsule（通心络胶囊, TXL） for patients with cardiac syndrome X（CSX）. Methods： Randomized controlled trials（RCTs） regarding TXL in the treatment of CSX were searched in Chinese Biomedicine Literature Database, China National Knowledge Infrastructure, Chinese Scientific Journal Database, Wanfang Database, Pub Med, EMBASE, Cochrane Central Register of Controlled Trial, websites of the Chinese and International Clinical Trial Registry platform up to June 30, 2015. The intervention was either TXL alone or TXL combined with conventional treatment, while the control intervention was conventional treatment with or without placebo. Data extraction, methodological quality assessment and data analyses were performed according to the Cochrane criteria. The primary outcome was a composite event of death, acute myocardial infarction（AMI）, angina requiring hospitalization, revascularization, and heart failure. The secondary outcome measures were angina symptom improvement, electrocardiograph（ECG） improvement, and serum endothelin-1（ET-1） level. The adverse events were also recorded. RevMan 5.3 software was applied for data analyses. Results： Twelve RCTs（696 patients） were included. Compared with conventional treatment, the addition of TXL to conventional treatment showed some benefits on relieving angina symptoms [risk ratio（RR）： 1.46, 95% confidence interval（CI）（1.25, 1.71）, P〈0.01], and improving ECG [RR： 1.45, 95% CI（1.21, 1.74）, P〈0.01]. The pooled result did not support a benefit of TXL on reducing the incidence of primary outcome [RR： 0.20, 95% CI（0.02, 1.61）, P=0.13]. In addition, TXL decreased serum ET-1 concentration of CSX patients [standardized mean number： –1.63, 95% CI（–2.29, –0.96）, P〈0.01]. No serious adverse events were reported. Conclusions： TXL documents potential benefits on attenuating angina symptoms, improving ECG and decreasing serum ET-1 level for CSX patients.
基金Priority Project of Tianjin Science Technical Commission (No. 05YFGDSF02200)Yan De-xin Foundation Project (No. 05-012)
文摘Objective： To evaluate the clinical effect of Liqi Kuanxiong Huoxue method （宽胸活血,LKH, traditional Chinese medicine, TCM therapeutic method for regulating qi, relieving chest stuffiness and promoting blood circulation） in treating patients with cardiac syndrome X （CSX）. Methods： The prospective, non-randomized controlled study was conducted on 51 selected patients with CSX, who were non-randomly assigned to 2 groups, the treated group treated with LKH in addition to the conventional treatment （32 patients）, and the control group treated with conventional treatment （19 patients） like nitrate, diltiazem hydrochloride, etc. The treatment course was 14 days. The changes of such symptoms as angina pectoris, TCM syndrome and indexes of treadmill exercise test before and after treatment were observed. Results： After treatment, such symptoms as chest pain and stuffy feeling and palpitation in the treated group were improved more than those in the control group （P〈0.05）; the total effective rate on angina pectoris and TCM syndrome in the treated group was better than that in the control group （P〈0.05）. The treadmill exercise test showed that the maximal metabolic equivalent （Max MET）, the time of angina onset and ST segment depression by 0.1 mV were obviously improved after treatment in both groups, but the improvement in the treated group was better than that in the control group respectively （P〈0.05）. Conclusion： The LKH method could reduce the frequency of angina attacks and improve the clinical condition of patients with CSX.
